Lillian L. Siu receives the Lifetime Achievement Award from the Chinese American Hematologist and Oncologist Network
Lillian L. Siu, MD, FAACR, was recently named the recipient of the Lifetime Achievement Award from the Chinese American Hematologist and Oncologist Network (CAHON).
Chinese American Hematologists and Oncologists Network (CAHON) was founded by Chinese American Hematologists and Oncologists in 2005. The primary goal of the Chinese American Hematologist and Oncologist Network (CAHON) is to foster communications amongst Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.
Each year CAHON recognizes members and supporters who have contributed significantly to advancing CAHON’s development and missions.
The Lifetime Achievement Award recognizes outstanding CAHON members who have made significant contributions and whose work have lasting impact in hematology and oncology, and/or, CAHON supporters and friends (non-CAHON members) who have made significant contribution and impact in hematology and oncology.
Lillian Siu is a leading cancer specialist in the field of oncology and drug development. Dr. Siu is a Professor of Medicine at the University of Toronto and serves as a senior medical oncologist at the Princess Margaret Cancer Centre, University Health Network. She is the President-Elect of the American Association for Cancer Research (AACR) for 2024-2025. Dr. Siu completed a fellowship in Oncopharmacology at the Princess Margaret Cancer Centre and a Clinical Research Fellowship in New Drug Development at The University of Texas Health Science Center in San Antonio.
She is a member of the AACR International Canada Board of Directors and AACR Finance and Audit Committee and a former member of the AACR Board of Directors. Dr. Sue has offered valuable guidance as a member of several AACR committees, including The Asian-American Task Force since 2023, The Clinical Trials Advisory Council (2023-present), The International Affairs Committee (2018-2020), The Regional Advisory Committee on Canada (2016-2019), Woman in Cancer Research Council (2013-2016), Clinical and Translational Cancer Research Grants Committee (2010), etc.
Dr. Siu served on the Board of Directors for the American Society of Clinical Oncology (ASCO) for a four-year term (2012-2016). She was the ASCO Conquer Cancer Foundation Grants Selection Committee Chair in 2009-10. She is on the editorial board for JAMA Oncology
Lillian Siu was the Co-Chair of the Nomination Committee of the Yvonne Award 2024 by OncoDaily.
Dr. Siu’s primary research area centers on the development of novel anticancer drugs, with a particular emphasis on phase I clinical trials and the treatment of head and neck malignancies.
Throughout her career, Siu has contributed significantly to the development of cytotoxic agents, targeted therapies, and immunotherapies.
American Association for Cancer Research (AACR) shared a post on LinkedIn congratulating Lillian Siu, adding:
“We congratulate AACR President-Elect Lillian L. Siu, MD, FAACR, who was named the recipient of the Lifetime Achievement Award from the Chinese American Hematologist and Oncologist Network (CAHON). Dr. Siu will be honored at CAHON’s 11th Annual New York Oncology Forum on October 5.”
